AVIR FY 2021 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$351M+622.5% YoY

Gross Profit

$184M52.4% margin

Operating Income

$138M39.4% margin

Net Income

$121M34.5% margin

EPS (Diluted)

$1.37

Cash Flow

Operating Cash Flow

-$87M

Free Cash Flow

-$87M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$773M

Total Liabilities

$63M

Stockholders' Equity

$710M

Cash & Equivalents

$764M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$351M	$49M	+622.5%
Gross Profit	$184M	$11M	+1635.7%
Operating Income	$138M	-$11M	+1354.6%
Net Income	$121M	-$11M	+1207.1%